scroll
for
more

meet basaglar®

(insulin glargine injection) 100 units/mL, an alternative basal insulin

BASAGLAR is a follow-on biologic to Lantus® (insulin glargine injection) 100 units/mL, with an identical amino acid sequence.1,2 The BASAGLAR pharmacodynamic (PD) profile demonstrated sustained glucose-lowering activity over 24 hours with no pronounced peak.1,3 Learn more about BASAGLAR KwikPen®.

Study design: Phase 1 randomized, double-blind, single-dose, 2-treatment, 4‑period, crossover, replicate-treatment, euglycemic clamp study with 91 healthy subjects.3

Select Safety Information
contraindications
BASAGLAR is contradicted during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one if its excipients.

Comparable

A1C reduction

BASAGLAR demonstrated noninferiority to US- or non-US-approved Lantus plus 2 or more OAMs (24 weeks)1,4:

  • A1C reduction from baseline
    • Noninferiority demonstrated: A1C reduction from baseline at 24 weeks1,4
    • BASAGLAR (n=376; baseline A1C: 8.35%): 1.29%
    • US- or non-US-approved Lantus (n=380; baseline A1C: 8.31%): 1.34%
    • No statistically significant difference. Difference of 0.052% (95% CI -0.070 to 0.175; p>0.05)
  • Percentage of patients achieving A1C <7%
    • Comparable percentage of patients that achieved A1C <7% at 24 weeks1,4
    • BASAGLAR (n=376; baseline A1C: 8.35%): 49%
    • US- or non-US-approved Lantus (n=380; baseline A1C: 8.31%): 53%
    • Secondary endpoint

Study design

  • 24-week, phase 3, randomized, double-blind trial of 756 adult patients with type 2 diabetes who were either insulin-naive and failed to achieve adequate glycemic control on at least 2 oral antidiabetic medications (OAMs) or were already on US- or non-US-approved Lantus along with 2 or more OAMs with adequate or inadequate glycemic control. The primary endpoint was noninferiority of BASAGLAR to US- or non-US-approved Lantus as measured by change in A1C from baseline at 24 weeks1,4
  • The starting dose for all insulin-naive patients was 10 units/day, while patients entering the study on US- or non-US-approved Lantus were randomized to either BASAGLAR or US- or non-US-approved Lantus at a dose equivalent to their prestudy US- or non-US-approved Lantus dose; BASAGLAR and US- or non-US-approved Lantus titration was patient-driven based on self-measured fasting plasma glucose with a target of <100 mg/dL4

CI=confidence interval; OAMs=oral anti-diabetic medications.

Select Safety Information
warnings and precautions
BASAGLAR KwikPen® must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

support

for diabetes management

along the way

We offer support resources designed to help staff and their patients regarding initiation and maintenance of insulin therapy. These include:

  • Training staff on topics ranging from general diabetes information to discharge planning
  • Teaching patients and their caregivers how to manage diabetes after they leave your care
  • Making the transition to long-acting insulin therapy achievable for patients

Talk with your Lilly Account Manager

to learn how we can support you in

providing quality diabetes care.

Talk with your Lilly Account Manager to learn how we can support you in providing quality diabetes care.